165 related articles for article (PubMed ID: 11523052)
1. Bcl-2 expression in pancreas development and pancreatic cancer progression.
Campani D; Esposito I; Boggi U; Cecchetti D; Menicagli M; De Negri F; Colizzi L; Del Chiaro M; Mosca F; Fornaciari G; Bevilacqua G
J Pathol; 2001 Aug; 194(4):444-50. PubMed ID: 11523052
[TBL] [Abstract][Full Text] [Related]
2. Expression of Bcl-2 and p53 correlates with the morphology of gastric neoplasia.
Kyokane K; Ito M; Sato Y; Ina K; Ando T; Kusugami K
J Pathol; 1998 Apr; 184(4):382-9. PubMed ID: 9664903
[TBL] [Abstract][Full Text] [Related]
3. Clinical contribution of bcl-2, p53 and Ki-67 proteins in pancreatic ductal adenocarcinoma.
Mäkinen K; Hakala T; Lipponen P; Alhava E; Eskelinen M
Anticancer Res; 1998; 18(1B):615-8. PubMed ID: 9568186
[TBL] [Abstract][Full Text] [Related]
4. Bcl-2 expression related to altered p53 protein and its impact on the progression of human pancreatic carcinoma.
Hu YX; Watanabe H; Ohtsubo K; Yamaguchi Y; Ha A; Motoo Y; Okai T; Sawabu N
Br J Cancer; 1999 Jun; 80(7):1075-9. PubMed ID: 10362119
[TBL] [Abstract][Full Text] [Related]
5. bax, but not bcl-2, influences the prognosis of human pancreatic cancer.
Friess H; Lu Z; Graber HU; Zimmermann A; Adler G; Korc M; Schmid RM; Büchler MW
Gut; 1998 Sep; 43(3):414-21. PubMed ID: 9863489
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of B2M and loss of ALK7 expression are associated with invasion, metastasis, and poor-prognosis of the pancreatic ductal adenocarcinoma.
Liu C; Yang Z; Li D; Liu Z; Miao X; Yang L; Zou Q; Yuan Y
Cancer Biomark; 2015; 15(6):735-43. PubMed ID: 26406402
[TBL] [Abstract][Full Text] [Related]
7. Apoptosis and expression of the Bcl-2 family of proteins and P53 in human pancreatic ductal adenocarcinoma.
Chen D; Zheng X; Kang D; Yan B; Liu X; Gao Y; Zhang K
Med Princ Pract; 2012; 21(1):68-73. PubMed ID: 22024503
[TBL] [Abstract][Full Text] [Related]
8. p53 accumulation confers prognostic information in resectable adenocarcinomas with ductal but not with intestinal differentiation in the pancreatic head.
Bergan A; Gladhaug IP; Schjolberg A; Bergan AB; Clausen OP
Int J Oncol; 2000 Nov; 17(5):921-6. PubMed ID: 11029493
[TBL] [Abstract][Full Text] [Related]
9. p53 overexpression in lymph node metastases predicts clinical outcome in ductal pancreatic cancer.
Campani D; Boggi U; Cecchetti D; Esposito I; Ceccarelli F; D'Antonio L; De Negri F; Mosca F; Bevilacqua G; Fornaciari G
Pancreas; 1999 Jul; 19(1):26-32. PubMed ID: 10416688
[TBL] [Abstract][Full Text] [Related]
10. Tumour suppressor protein (p53), apoptosis inhibiting protein (Bcl-2) and proliferating cell nuclear antigen (PCNA) expressions in a rat pancreatic tumour model.
Mäkinen K; Loimas S; Hakala T; Eskelinen M
Anticancer Res; 2007; 27(1A):23-6. PubMed ID: 17352211
[TBL] [Abstract][Full Text] [Related]
11. Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.
Piao J; Liu S; Xu Y; Wang C; Lin Z; Qin Y; Liu S
Exp Mol Pathol; 2015 Feb; 98(1):1-6. PubMed ID: 25445504
[TBL] [Abstract][Full Text] [Related]
12. Expression of Bcl-2 in lung neuroendocrine tumours: comparison with p53.
Wang DG; Johnston CF; Sloan JM; Buchanan KD
J Pathol; 1998 Mar; 184(3):247-51. PubMed ID: 9614375
[TBL] [Abstract][Full Text] [Related]
13. An immunohistochemical study of the expression of bcl-2 and p53 oncoproteins in pancreatic intraepithelial neoplasia and pancreatic cancer.
Tomaszewska R; Karcz D; Stachura J
Int J Pancreatol; 1999 Dec; 26(3):163-71. PubMed ID: 10732293
[TBL] [Abstract][Full Text] [Related]
14. Apoptosis and cell-cycle regulatory proteins in colorectal carcinoma: relationship to tumour stage and patient survival.
Elkablawy MA; Maxwell P; Williamson K; Anderson N; Hamilton PW
J Pathol; 2001 Aug; 194(4):436-43. PubMed ID: 11523051
[TBL] [Abstract][Full Text] [Related]
15. Correlation of Bcl-2 and p53 expression in primary breast tumors and corresponding metastatic lymph nodes.
Arun B; Kilic G; Yen C; Foster B; Yardley D; Gaynor R; Ashfaq R
Cancer; 2003 Dec; 98(12):2554-9. PubMed ID: 14669273
[TBL] [Abstract][Full Text] [Related]
16. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
[TBL] [Abstract][Full Text] [Related]
17. Analysis of p53, p21WAF1, and TGF-beta1 in human ductal adenocarcinoma of the pancreas: TGF-beta1 protein expression predicts longer survival.
Coppola D; Lu L; Fruehauf JP; Kyshtoobayeva A; Karl RC; Nicosia SV; Yeatman TJ
Am J Clin Pathol; 1998 Jul; 110(1):16-23. PubMed ID: 9661918
[TBL] [Abstract][Full Text] [Related]
18. Relationship between apoptosis regulator proteins (bcl-2 and p53) and Gleason score in prostate cancer.
Karaburun Paker S; Kilicarslan B; Ciftcioglu AM; Oztekin S; Sargin FC; Erdogru T; Baykara M
Pathol Oncol Res; 2001; 7(3):209-12. PubMed ID: 11692148
[TBL] [Abstract][Full Text] [Related]
19. DEK protein overexpression predicts poor prognosis in pancreatic ductal adenocarcinoma.
Sun J; Bi F; Yang Y; Zhang Y; Jin A; Li J; Lin Z
Oncol Rep; 2017 Feb; 37(2):857-864. PubMed ID: 27959420
[TBL] [Abstract][Full Text] [Related]
20. Identification of ANXA1 as a lymphatic metastasis and poor prognostic factor in pancreatic ductal adenocarcinoma.
Liu QH; Shi ML; Bai J; Zheng JN
Asian Pac J Cancer Prev; 2015; 16(7):2719-24. PubMed ID: 25854353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
